These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 26340507)

  • 1. Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
    Yang LX; Gao Q; Shi JY; Wang ZC; Zhang Y; Gao PT; Wang XY; Shi YH; Ke AW; Shi GM; Cai JB; Liu WR; Duan M; Zhao YJ; Ji Y; Gao DM; Zhu K; Zhou J; Qiu SJ; Cao Y; Tang QQ; Fan J
    Hepatology; 2015 Dec; 62(6):1804-16. PubMed ID: 26340507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
    J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Operative ubiquitin-specific protease 22 deubiquitination confers a more invasive phenotype to cholangiocarcinoma.
    Tian Y; Tang B; Wang C; Wang Y; Mao J; Yao Y; Gao Z; Liang R; Ye M; Cai S; Wang L
    Cell Death Dis; 2021 Jul; 12(7):678. PubMed ID: 34226501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells.
    Yang H; Lu X; Liu Z; Chen L; Xu Y; Wang Y; Wei G; Chen Y
    Oncotarget; 2015 Mar; 6(8):6310-25. PubMed ID: 25749036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma.
    Lixin S; Wei S; Haibin S; Qingfu L; Tiemin P
    Mol Carcinog; 2020 Dec; 59(12):1371-1381. PubMed ID: 33052627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition.
    Clapéron A; Mergey M; Nguyen Ho-Bouldoires TH; Vignjevic D; Wendum D; Chrétien Y; Merabtene F; Frazao A; Paradis V; Housset C; Guedj N; Fouassier L
    J Hepatol; 2014 Aug; 61(2):325-32. PubMed ID: 24704591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
    Liu LZ; He YZ; Dong PP; Ma LJ; Wang ZC; Liu XY; Duan M; Yang LX; Shi JY; Zhou J; Fan J; Gao Q; Wang XY
    Oncotarget; 2016 Nov; 7(46):75210-75220. PubMed ID: 27655691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.
    Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR
    Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF-κB pathway-mediated inflammatory responses.
    Liu B; Yan S; Jia Y; Ma J; Wu S; Xu Y; Shang M; Mao A
    FEBS J; 2016 Oct; 283(20):3839-3850. PubMed ID: 27616304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortalin promotes cell proliferation and epithelial mesenchymal transition of intrahepatic cholangiocarcinoma cells in vitro.
    Kang Q; Cai JB; Dong RZ; Liu LX; Zhang C; Zhang PF; Zou H; Xie N; Zhang L; Zhang XY; Song ZJ; Dong ZR; Hu MY; Huang XY; Zhang XW; Ke AW; Shi GM
    J Clin Pathol; 2017 Aug; 70(8):677-683. PubMed ID: 28096273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma.
    Okamoto K; Tajima H; Nakanuma S; Sakai S; Makino I; Kinoshita J; Hayashi H; Nakamura K; Oyama K; Nakagawara H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Harada S; Wakayama T; Iseki S; Ohta T
    Int J Oncol; 2012 Aug; 41(2):573-82. PubMed ID: 22664794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of epithelial-mesenchymal transition-related markers according to cell dedifferentiation: clinical implications as an independent predictor of poor prognosis in cholangiocarcinoma.
    Ryu HS; Chung JH; Lee K; Shin E; Jing J; Choe G; Kim H; Xu X; Lee HE; Kim DG; Lee H; Jang JJ
    Hum Pathol; 2012 Dec; 43(12):2360-70. PubMed ID: 23084587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenomedullin promotes intrahepatic cholangiocellular carcinoma metastasis and invasion by inducing epithelial-mesenchymal transition.
    Zhou C; Zheng Y; Li L; Zhai W; Li R; Liang Z; Zhao L
    Oncol Rep; 2015 Aug; 34(2):610-6. PubMed ID: 26043778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 14-3-3ζ and aPKC-ι synergistically facilitate epithelial-mesenchymal transition of cholangiocarcinoma via GSK-3β/Snail signaling pathway.
    Yang Y; Liu Y; He JC; Wang JM; Schemmer P; Ma CQ; Qian YW; Yao W; Zhang J; Qi WP; Fu Y; Feng W; Yang T
    Oncotarget; 2016 Aug; 7(34):55191-55210. PubMed ID: 27409422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific prognostic factors in hepatitis B virus-related and non-hepatitis B virus-related intrahepatic cholangiocarcinoma after macroscopic curative resection.
    Huang J; Wang X; Zhu Y; Wang Z; Li J; Xu D; Wang S; Li TE; Lu L
    J Surg Oncol; 2019 Jan; 119(1):40-46. PubMed ID: 30480811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ANXA8 down-regulation by EGF-FOXO4 signaling is involved in cell scattering and tumor metastasis of cholangiocarcinoma.
    Lee MJ; Yu GR; Yoo HJ; Kim JH; Yoon BI; Choi YK; Kim DG
    Gastroenterology; 2009 Sep; 137(3):1138-50, 1150.e1-9. PubMed ID: 19376120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SSH1 promotes progression of intrahepatic cholangiocarcinoma via p38 MAPK-CXCL8 axis.
    Chen F; Aye L; Yu L; Liu L; Liu Y; Lin Y; Gao D; Gao Q; Zhang S
    Carcinogenesis; 2023 May; 44(3):232-241. PubMed ID: 36857607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
    Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
    Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma.
    Liao W; Du J; Li L; Wu X; Chen X; Feng Q; Xu L; Chen X; Liao M; Huang J; Yuan K; Zeng Y
    J Exp Clin Cancer Res; 2023 May; 42(1):125. PubMed ID: 37198696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Septin 9 expression regulates 'don't eat me' signals and identifies an immune-epithelial class of intrahepatic cholangiocarcinoma.
    Cai TT; Desterke C; Peng J; Agnetti J; Song P; Ouazib D; Dos Santos A; Guettier C; Samuel D; Gassama-Diagne A
    Mol Oncol; 2024 Oct; 18(10):2369-2392. PubMed ID: 39082897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.